This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hakala, J. K. Articles by Kovanen, P. T. Search for Related Content PubMed PubMed Citation Articles by Hakala, J. K. Articles by Kovanen, P. T. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB HEPARIN Related Collections Pathophysiology Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1276-1283.)
© 1999 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Lipolytic Modification of LDL by Phospholipase A₂ Induces Particle Aggregation in the Absence and Fusion in the Presence of Heparin

Jukka K. Hakala; Katariina Öörni; Mika Ala-Korpela; Petri T. Kovanen

From the Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki.

Correspondence to Petri T. Kovanen, Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. E-mail Petri.Kovanen{at}wri.fi

Abstract—One of the first events in atherogenesis is modification of low density lipoprotein (LDL) particles in the arterial wall with ensuing formation of aggregated and fused lipid droplets. The accumulating particles are relatively depleted in phosphatidylcholine (PC). Recently, secretory phospholipase A₂ (PLA₂), an enzyme capable of hydrolyzing LDL PC into fatty acid and lysoPC molecules, has been found in atherosclerotic arteries. There is also evidence that both LDL and PLA₂ bind to the glycosaminoglycan (GAG) chains of extracellular proteoglycans in the arterial wall. Here we studied the effect of heparin GAG on the lipolytic modification of LDL by PLA₂. Untreated LDL, heparin-treated LDL, and heparin-bound LDL were lipolyzed with bee venom PLA₂. In the presence of albumin, lipolysis resulted in aggregation in all 3 preparations of the LDL particles. Lipolysis of untreated LDL did not result in aggregation if albumin was absent from the reaction medium, and the lipolytic products accumulated in the particles rendering them negatively charged. However, heparin-treated and heparin-bound lipolyzed LDL particles aggregated even in the absence of albumin. Importantly, in the presence of albumin, some of the heparin-treated and heparin-bound lipolyzed LDL particles fused, the proportion of fused particles being substantially greater when LDL was bound to heparin during lipolysis. In summary, lipolysis of LDL PC by PLA₂ under physiological conditions, which allow transfer of the lipolytic degradation products to albumin, leads to fusion of LDL particles in the presence, but not in the absence, of heparin. Thus, it is possible that within the GAG meshwork of the arterial intima, PLA₂-induced modification of LDL is one source of the lipid droplets during atherogenesis.

Key Words: aggregation • fusion • heparin • LDL • phospholipase A₂

This article has been cited by other articles:

				K. Oorni and P. T. Kovanen PLA2-V: A Real Player in Atherogenesis Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 445 - 447. [Full Text] [PDF]

				M. Hashimoto, T. Kadowaki, T. Tsukuba, and K. Yamamoto Selective Proteolysis of Apolipoprotein B-100 by Arg-Gingipain Mediates Atherosclerosis Progression Accelerated by Bacterial Exposure J. Biochem., November 1, 2006; 140(5): 713 - 723. [Abstract] [Full Text] [PDF]

				U. J. F. Tietge, D. Pratico, T. Ding, C. D. Funk, R. B. Hildebrand, T. Van Berkel, and M. Van Eck Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress J. Lipid Res., August 1, 2005; 46(8): 1604 - 1614. [Abstract] [Full Text] [PDF]

				A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res., March 1, 2005; 46(3): 389 - 403. [Abstract] [Full Text] [PDF]

				C. Flood, M. Gustafsson, R. E. Pitas, L. Arnaboldi, R. L. Walzem, and J. Boren Molecular Mechanism for Changes in Proteoglycan Binding on Compositional Changes of the Core and the Surface of Low-Density Lipoprotein-Containing Human Apolipoprotein B100 Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 564 - 570. [Abstract] [Full Text]

				H. W.M Niessen, P. A.J Krijnen, C. A Visser, C. J.L.M Meijer, and C Erik Hack Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res, October 15, 2003; 60(1): 68 - 77. [Abstract] [Full Text] [PDF]

				J. K. Hakala, R. Oksjoki, P. Laine, H. Du, G. A. Grabowski, P. T. Kovanen, and M. O. Pentikainen Lysosomal Enzymes Are Released From Cultured Human Macrophages, Hydrolyze LDL In Vitro, and Are Present Extracellularly in Human Atherosclerotic Lesions Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1430 - 1436. [Abstract] [Full Text] [PDF]

				K. Hanasaki, K. Yamada, S. Yamamoto, Y. Ishimoto, A. Saiga, T. Ono, M. Ikeda, M. Notoya, S. Kamitani, and H. Arita Potent Modification of Low Density Lipoprotein by Group X Secretory Phospholipase A2 Is Linked to Macrophage Foam Cell Formation J. Biol. Chem., August 2, 2002; 277(32): 29116 - 29124. [Abstract] [Full Text] [PDF]

				E. Hurt-Camejo, G. Camejo, H. Peilot, K. Oorni, and P. Kovanen Phospholipase A2 in Vascular Disease Circ. Res., August 17, 2001; 89(4): 298 - 304. [Abstract] [Full Text] [PDF]

				M. O. Pentikäinen, M. T. Hyvönen, K. Öörni, T. Hevonoja, A. Korhonen, E. M. P. Lehtonen-Smeds, M. Ala-Korpela, and P. T. Kovanen Altered phospholipid-apoB-100 interactions and generation of extra membrane material in proteolysis-induced fusion of LDL particles J. Lipid Res., June 1, 2001; 42(6): 916 - 922. [Abstract] [Full Text]

				J. R. Guyton Phospholipid Hydrolytic Enzymes in a 'Cesspool' of Arterial Intimal Lipoproteins : A Mechanism for Atherogenic Lipid Accumulation Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 884 - 886. [Full Text] [PDF]

				J. K. Hakala, K. Oorni, M. O. Pentikainen, E. Hurt-Camejo, and P. T. Kovanen Lipolysis of LDL by Human Secretory Phospholipase A2 Induces Particle Fusion and Enhances the Retention of LDL to Human Aortic Proteoglycans Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 1053 - 1058. [Abstract] [Full Text] [PDF]

				K. Öörni, M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions J. Lipid Res., November 1, 2000; 41(11): 1703 - 1714. [Abstract] [Full Text]

				A. Niemann-Jonsson, P. Dimayuga, S. Jovinge, F. Calara, M. P. S. Ares, G. N. Fredrikson, and J. Nilsson Accumulation of LDL in Rat Arteries Is Associated With Activation of Tumor Necrosis Factor-{alpha} Expression Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2205 - 2211. [Abstract] [Full Text] [PDF]

				P. T. Kovanen and M. O. Pentikainen Secretory Group II Phospholipase A2 : A Newly Recognized Acute-Phase Reactant With a Role in Atherogenesis Circ. Res., March 31, 2000; 86(6): 610 - 612. [Full Text] [PDF]

				W.-Y. Zhang, I. Ishii, and H. S. Kruth Plasmin-mediated Macrophage Reversal of Low Density Lipoprotein Aggregation J. Biol. Chem., October 13, 2000; 275(42): 33176 - 33183. [Abstract] [Full Text] [PDF]